<ѻýҕl>How Can Cancer Risk Be Cut in Communities Exposed to Toxins?ѻýҕl> Group outlines plan to bring the latest testing and treatment to medically underserved minorities Jan 25, 2024
<ѻýҕl>EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Riskѻýҕl> Findings don't tell us to stop these drugs, researcher says, but should guide clinical decisions Jan 13, 2024
<ѻýҕl>Hypofractionated Chemoradiation With Adaptive SABR Appeared Effective in NSCLCѻýҕl> Dose of 70 Gy in 15 fractions showed favorable balance between safety and efficacy in small trial Jan 12, 2024
<ѻýҕl>Cryobiopsy and Forceps Biopsy Go Head-to-Head for Diagnosing Lung Lesionsѻýҕl> When added to needle aspiration, one method yielded better samples for molecular testing in NSCLC Jan 09, 2024
<ѻýҕl>Futile Immunotherapy for Cancer Grows More Commonѻýҕl> Occurs most often at non-academic and low-volume centers Jan 04, 2024
<ѻýҕl>Cancer Patients Face Frightening Delays in Treatment Approvalsѻýҕl> "For them to take weeks -- up to months -- to provide an authorization is ridiculous" Dec 30, 2023
<ѻýҕl>Homelessness Tied to Worse Cancer Outcomes Among Veteransѻýҕl> However, all-cause mortality rates in lung, colon cancer lower versus other healthcare settings Dec 21, 2023
<ѻýҕl>Grappling With Our Deadliest Cancerѻýҕl> Here are essential steps to improve lung cancer screening Dec 10, 2023
<ѻýҕl>With an Old X-Ray, AI Can Detect High Risk of Lung Cancer in Never Smokersѻýҕl> Tool could identify nonsmokers most likely to benefit from low-dose CT screening Nov 29, 2023
<ѻýҕl>Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutationsѻýҕl> Researchers suggest the drug is a promising option for this rare subgroup Nov 22, 2023
<ѻýҕl>FDA OKs New Option for Advanced ROS1-Positive Lung Cancerѻýҕl> Drug achieved high response rates in TKI-naive and TKI-pretreated patients Nov 16, 2023
<ѻýҕl>Lung Cancer Survival High at 20 Years With Screen-Detected Tumorsѻýҕl> After two decades, lung cancer-specific survival remained at 81% in I-ELCAP program Nov 07, 2023
<ѻýҕl>Lambert-Eaton Myasthenic Syndrome Underdiagnosed Alongside SCLC in the U.S.ѻýҕl> Findings suggest patients with SCLC are not screened for LEMS, despite their association Nov 02, 2023
<ѻýҕl>ACS: Millions More Should Get Lung Cancer Screeningѻýҕl> Notably, new recommendations say it doesn't matter when a person quit smoking Nov 01, 2023
<ѻýҕl>The Exciting Potential of Antibody-Drug Conjugates in Lung Cancerѻýҕl> Roy Herbst, MD, PhD, leads a discussion on ADCs targeting TROP2, HER2, and HER3 Oct 30, 2023 video
<ѻýҕl>New Options Challenge Standard Treatments in EGFR-Mutant NSCLCѻýҕl> Amivantamab-based regimens improved oncologic outcomes, but with more side effects Oct 25, 2023
<ѻýҕl>ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancerѻýҕl> Adjuvant alectinib reduces disease-free survival hazard by 76% Oct 24, 2023
<ѻýҕl>Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancersѻýҕl> Still some unanswered questions about benefit over other drug regimens, expert says Oct 24, 2023
<ѻýҕl>Targeting KRAS in NSCLC: Recent Progress and New Approachesѻýҕl> Roy Herbst, MD, PhD, leads a discussion on current and emerging treatments available Oct 23, 2023 video
<ѻýҕl>New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertionsѻýҕl> Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses Oct 23, 2023
<ѻýҕl>RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLCѻýҕl> Two randomized studies demonstrate significantly improved PFS against standard regimens Oct 22, 2023
<ѻýҕl>Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyondѻýҕl> Tarlatamab achieves 40% overall response rate at the dose selected for continued evaluation Oct 22, 2023
<ѻýҕl>Pembrolizumab Wins FDA Approval in Operable Lung Cancerѻýҕl> Checkpoint inhibitor demonstrated significant survival improvement in perioperative setting Oct 17, 2023
<ѻýҕl>New Lung Cancer Cases Are Higher in Younger Women vs Menѻýҕl> And the higher incidence rates now extend to women ages 50 to 54 as well Oct 12, 2023
<ѻýҕl>Combination Therapy Wins FDA Approval for BRAF-Mutated NSCLCѻýҕl> Encorafenib plus binimetinib led to 75% ORR in untreated patients, 59% in treated patients Oct 12, 2023
<ѻýҕl>Primary Care Intervention Improved Follow-Up of Abnormal Cancer Screening Resultsѻýҕl> Follow-up testing within 120 days was improved with EHR reminders, patient outreach, navigation Oct 10, 2023
<ѻýҕl>Sotorasib's Confirmatory Data in NSCLC Unreliable, Says FDA Panelѻýҕl> But agency doesn't plan to immediately push for KRAS inhibitor's withdrawal Oct 05, 2023
<ѻýҕl>Can ctDNA Guide Radiation Use in Oligometastatic NSCLC?ѻýҕl> Detectable circulating tumor DNA before radiotherapy linked with worse survival Oct 05, 2023
<ѻýҕl>FDA Staff Highly Skeptical of Confirmatory Data on KRAS Inhibitor in NSCLCѻýҕl> Reviewers see potentially tiny PFS benefit with sotorasib, raise concerns over "systemic bias" Oct 04, 2023
<ѻýҕl>The White House Cancer Moonshot Is a Dudѻýҕl> We're failing to take simple steps to reduce one of the biggest causes of cancer Sep 22, 2023
<ѻýҕl>Another Win for Biomarker-Driven Thromboprophylaxis for Patients With Cancerѻýҕl> Threefold risk reduction with enoxaparin in high-risk gastrointestinal, lung cancers Sep 21, 2023
<ѻýҕl>Individualized SABR for Lung Tumors Yields Low Recurrence Ratesѻýҕl> Strategy also results in low rates of severe toxic effects Sep 14, 2023
<ѻýҕl>IMRT Best for Locally Advanced NSCLC, Study Suggestsѻýҕl> Technique reduces risk of severe lung toxicity and radiation to the heart compared with 3D-CRT Sep 13, 2023
<ѻýҕl>Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLCѻýҕl> Confirmed responses reached 29.8% in heavily pretreated patients Sep 13, 2023
<ѻýҕl>Study Questions Use of Aggressive Surgery in Early Mesotheliomaѻýҕl> Randomized data suggest surgery increases risk of death by 28% over first 42 months Sep 12, 2023
<ѻýҕl>Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancerѻýҕl> Osimertinib plus chemotherapy improved PFS by nearly 9 months versus targeted agent alone Sep 12, 2023
<ѻýҕl>First-Line Triplet Yields 'Striking' OS Result in Extensive-Stage SCLCѻýҕl> Median overall survival reached 19.3 months in Chinese trial Sep 11, 2023
<ѻýҕl>How the Chemotherapy Shortage Is Affecting Frontline Cliniciansѻýҕl> "How are we here in 2023 having some of these discussions?" bemoans gynecologic cancer expert Sep 08, 2023 video
<ѻýҕl>Novel KRAS Inhibitor Leads to Durable Responses in Multiple Tumor Typesѻýҕl> More than half of patients with NSCLC, more than a third of those with CRC responded to divarasib Aug 23, 2023
<ѻýҕl>Removing Race-Corrected Pulmonary Function Tests May Alter Lung Cancer Careѻýҕl> Path to eliminating these tests, while crucial, will be challenging, researchers say Aug 16, 2023